Kite Blasts Higher After Great Non-Hodgkin lymphoma Data Released #CAR-T

Now this is some great data.

Some 76 percent of patients taking the drug, called KTE-C19, showed significant tumor shrinkage, including 47 percent who had no remaining signs of cancer at least three months after receiving the treatment, Kite said.

So that is a 50-50 chance of complete remission after three months of treatment? That is an incredibly good deal. I am convinced CAR-T and immunotherapy are going to lead to a cure for cancer in the next decade or so.